Saturday 17 October 2026
Export AAPG’s income statement to Excel — free account
Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
15.37
0.68
+4.63%
Follow AAPG
Ascentage Pharma Group International - Unsponsored ADR (AAPG) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GHRS GH Research PLC compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| ANAB AnaptysBio, Inc. compare | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| INBX Inhibrx Biosciences, Inc. compare | n/m |
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| OMER Omeros Corporation compare | 9.5× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)